186 related articles for article (PubMed ID: 38612604)
1. MicroRNA Expression Profiles in Human Samples and Cell Lines Revealed Nine miRNAs Associated with Cisplatin Resistance in High-Grade Serous Ovarian Cancer.
Flores-Colón M; Rivera-Serrano M; Reyes-Burgos VG; Rolón JG; Pérez-Santiago J; Marcos-Martínez MJ; Valiyeva F; Vivas-Mejía PE
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612604
[TBL] [Abstract][Full Text] [Related]
2. miR-142-5p enhances cisplatin-induced apoptosis in ovarian cancer cells by targeting multiple anti-apoptotic genes.
Li X; Chen W; Jin Y; Xue R; Su J; Mu Z; Li J; Jiang S
Biochem Pharmacol; 2019 Mar; 161():98-112. PubMed ID: 30639456
[TBL] [Abstract][Full Text] [Related]
3. miR-219-5p attenuates cisplatin resistance of ovarian cancer by inactivating Wnt/β-catenin signaling and autophagy via targeting HMGA2.
Song Z; Liao C; Yao L; Xu X; Shen X; Tian S; Wang S; Xing F
Cancer Gene Ther; 2023 Apr; 30(4):596-607. PubMed ID: 36494581
[TBL] [Abstract][Full Text] [Related]
4. MiR-30a-5p Enhances Cisplatin Sensitivity by Downregulating RIF1 in Ovarian Cancer.
Yao W; Wang Y; Huang M; Zhou J; Zheng R; Jin C; Zhang Y
Ann Clin Lab Sci; 2023 May; 53(3):418-426. PubMed ID: 37437929
[TBL] [Abstract][Full Text] [Related]
5. [Identification of key molecules in miRNA-mRNA regulatory network associated with high-grade serous ovarian cancer recurrence using bioinformatic analysis].
Zhang P; He M; Zeng Y; Cai X
Nan Fang Yi Ke Da Xue Xue Bao; 2023 Jan; 43(1):8-16. PubMed ID: 36856205
[TBL] [Abstract][Full Text] [Related]
6. MiR-149-3p promotes the cisplatin resistance and EMT in ovarian cancer through downregulating TIMP2 and CDKN1A.
Wang J; Liu L
J Ovarian Res; 2021 Nov; 14(1):165. PubMed ID: 34798882
[TBL] [Abstract][Full Text] [Related]
7. Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.
Chen Y; Cao XY; Li YN; Qiu YY; Li YN; Li W; Wang H
Am J Physiol Cell Physiol; 2018 Aug; 315(2):C225-C235. PubMed ID: 29719173
[TBL] [Abstract][Full Text] [Related]
8. The Profile of MicroRNA Expression and Potential Role in the Regulation of Drug-Resistant Genes in Cisplatin- and Paclitaxel-Resistant Ovarian Cancer Cell Lines.
Kazmierczak D; Jopek K; Sterzynska K; Nowicki M; Rucinski M; Januchowski R
Int J Mol Sci; 2022 Jan; 23(1):. PubMed ID: 35008952
[TBL] [Abstract][Full Text] [Related]
9. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-625-3p improved proliferation and involved chemotherapy resistance via targeting PTEN in high grade ovarian serous carcinoma.
Zhong L; Liu X; Wang L; Liu Y; Zhang D; Zhao Y
J Ovarian Res; 2022 Jan; 15(1):7. PubMed ID: 35027053
[TBL] [Abstract][Full Text] [Related]
11. Expression of miR-224-5p is associated with the original cisplatin resistance of ovarian papillary serous carcinoma.
Zhao H; Bi T; Qu Z; Jiang J; Cui S; Wang Y
Oncol Rep; 2014 Sep; 32(3):1003-12. PubMed ID: 25017423
[TBL] [Abstract][Full Text] [Related]
12. miR-18a-5p derived from mesenchymal stem cells-extracellular vesicles inhibits ovarian cancer cell proliferation, migration, invasion, and chemotherapy resistance.
Wang X; Jiang L; Liu Q
J Transl Med; 2022 Jun; 20(1):258. PubMed ID: 35672774
[TBL] [Abstract][Full Text] [Related]
13. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
[TBL] [Abstract][Full Text] [Related]
14. MiR-30a-5p/CHD1 axis enhances cisplatin sensitivity of ovarian cancer cells via inactivating the Wnt/β-catenin pathway.
Wang X; Zhao H; Wang P; Zhang J; Li N; Liu Y; Zhang F; Yu Y
Anticancer Drugs; 2022 Nov; 33(10):989-998. PubMed ID: 36206129
[TBL] [Abstract][Full Text] [Related]
15. Identification of upregulated exosomal miRNAs between A2780 and A2780/DDP human ovarian cancer cells by high-throughput sequencing.
Wang H; Liu L; Liu Q; Zheng J; Zheng Q; Chen Y; Xia H; Wu Q; Sun Y
J Ovarian Res; 2023 May; 16(1):94. PubMed ID: 37179363
[TBL] [Abstract][Full Text] [Related]
16. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3β/β-catenin signaling pathway.
Dai J; Wei R; Zhang P; Kong B
J Transl Med; 2019 Jun; 17(1):190. PubMed ID: 31171023
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA expression in ovarian carcinoma and its correlation with clinicopathological features.
Lee H; Park CS; Deftereos G; Morihara J; Stern JE; Hawes SE; Swisher E; Kiviat NB; Feng Q
World J Surg Oncol; 2012 Aug; 10():174. PubMed ID: 22925189
[TBL] [Abstract][Full Text] [Related]
19. Circ_0007841 knockdown confers cisplatin sensitivity to ovarian cancer cells by down-regulation of NFIB expression in a miR-532-5p-dependent manner.
Gao Y; Huang Y
J Chemother; 2023 Apr; 35(2):117-130. PubMed ID: 35380509
[TBL] [Abstract][Full Text] [Related]
20. Transcriptomic analysis reveals tumor stage- or grade-dependent expression of miRNAs in serous ovarian cancer.
Berkel C; Cacan E
Hum Cell; 2021 May; 34(3):862-877. PubMed ID: 33576947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
